P1346
P185
Modeling the within-host dynamics of HIV infectionEstimating drug efficacy and viral dynamic parameters: HIV and HCVViral kinetic modeling: state of the artModelling hepatitis C therapy--predicting effects of treatmentZika viral dynamics and shedding in rhesus and cynomolgus macaquesMathematical Modeling of Subgenomic Hepatitis C Virus Replication in Huh-7 CellsEarly ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirinModeling hepatitis C virus dynamics: Liver regeneration and critical drug efficacyWhy are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?Modeling Subgenomic Hepatitis C Virus RNA Kinetics during Treatment with Alpha InterferonEstimating lymphocyte division and death rates from CFSE dataViral and latent reservoir persistence in HIV-1-infected patients on therapyAccelerated immunodeficiency by anti-CCR5 treatment in HIV infectionTreatment-mediated alterations in HIV fitness preserve CD4+ T cell counts but have minimal effects on viral loadTriple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virusElucidation of hepatitis C virus transmission and early diversification by single genome sequencingSpontaneous clearance of viral infections by mesoscopic fluctuationsImpact of different oseltamivir regimens on treating influenza A virus infection and resistance emergence: insights from a modelling studyA hepatitis C virus infection model with time-varying drug effectiveness: solution and analysisResidual Viremia in Treated HIV+ IndividualsModeling the Effects of Morphine on Simian Immunodeficiency Virus DynamicsMolecular clock of HIV-1 envelope genes under early immune selectionScaling aspects of lymphocyte traffickingZika Virus Persistence in the Central Nervous System and Lymph Nodes of Rhesus MonkeysIdentification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infectionQuantifying the early immune response and adaptive immune response kinetics in mice infected with influenza A virus.Higher level of replication efficiency of 2009 (H1N1) pandemic influenza virus than those of seasonal and avian strains: kinetics from epithelial cell culture and computational modelingInfluenza A virus infection kinetics: quantitative data and models.Effect of 1918 PB1-F2 expression on influenza A virus infection kinetics.Combination antiviral therapy for influenza: predictions from modeling of human infections.Kinetics of coinfection with influenza A virus and Streptococcus pneumoniae.Kinetics of influenza A virus infection in humans.Treatment of hepatitis C with an interferon-based lead-in phase: a perspective from mathematical modellingEstimates of intracellular delay and average drug efficacy from viral load data of HIV-infected individuals under antiretroviral therapy.Determining thymic output quantitatively: using models to interpret experimental T-cell receptor excision circle (TREC) data.Modeling T cell proliferation and death in vitro based on labeling data: generalizations of the Smith-Martin cell cycle model.Dynamic correlation between intrahost HIV-1 quasispecies evolution and disease progression.Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy.High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men.CD8+ lymphocytes control viral replication in SIVmac239-infected rhesus macaques without decreasing the lifespan of productively infected cells.
P50
Q21245370-4E99BB01-399F-468D-B20F-79F856A2ABA9Q22252850-0C7AB019-C989-4F73-9898-21D3883E4F8DQ26824655-0AFCC056-42D8-44DA-9A84-8136C85F78D6Q26864673-4D43A196-B22A-46D0-BBDF-3AF185CEF063Q27087751-4E4E78AB-B676-44E8-901B-520B478B6754Q27478039-05096A42-BBE9-4134-9AF4-E039E2E41265Q27481147-DCD6A3C1-B616-4095-A084-D3C75E050BD7Q27485474-F24F3249-FCCC-4589-88DE-D53420EA992AQ27487167-565FE568-3172-4837-A795-4859B42E7BBAQ27488804-891A29F8-CDBD-4268-84D3-9B99263C2513Q28251322-783B46C9-5F2C-4750-8EC3-3B5FAD6D5FC6Q28469057-D7410B84-FC8E-4248-AFF5-932B25FD2050Q28475890-251BC585-9C17-4B04-8E4B-494A6F186B87Q28476227-D5578CEE-283F-441B-8394-05A7E739818AQ28478637-A5FB6CDE-B34B-47AD-8408-513F7820A38DQ28482493-21771F26-DACC-422B-BDB7-66C403E97F38Q28484092-9353D854-6D58-4A97-AE74-00FA980D688AQ28537982-C1140EE4-9A31-47E8-8948-CBDF57B7D08FQ28541682-80EBF531-57D8-4ABA-AB8F-B210AD473559Q28552126-6EF50A09-A736-4A7B-8658-DBD7877B089FQ28554352-A07B3608-AF3F-4DEA-AD7E-582CABABABD7Q28601925-287301FA-82B6-4315-BFAC-F182AB18EC61Q28751862-F2FB7F6C-E86A-4D96-B304-0BACCB337D2DQ29587262-C3901C1D-C55A-46D1-B089-878196383D71Q29619510-189C9382-436A-4010-B5B7-3D576F09EC87Q30388405-BE4F261D-E2E8-42F7-8479-E091301D1B1DQ30396110-AA86E662-740A-4B97-8795-FAD22E4FF249Q30398031-0EA056E6-DC85-4E11-8721-49AE03418760Q30400455-C8069A62-CCE6-4BE9-838C-A8262198D0DBQ30414648-7B6ADCCD-13F4-46AD-9988-FF400682FBF4Q30429002-99D3DC87-F674-40DB-B235-5E171C258175Q30445615-C1807F79-0FF8-4C23-A2D2-4EEB70DB7336Q30583856-0262C37C-3AEC-4DEF-BFFC-FB04F2A609E3Q30929606-67CC49B9-485B-468B-B64B-77CE74798D90Q31105898-2186C34E-6ED9-4461-9212-60392A40AD4DQ31121872-9BBC92A8-3018-4EA0-ABC4-DA750423C041Q33392723-07FE9A1F-3B92-435C-95EA-76137CCBD7EDQ33510903-2A88AA07-C90A-4A75-9910-940A451D8F58Q33582135-2415178E-3924-4B1C-BE82-EE273C791F96Q33618007-6C0B2EC0-A410-4BAD-8277-BFBB449D7733
P50
description
US-amerikanischer Biophysiker
@de
biofysicus
@nl
biophysicist
@en
name
Alan Perelson
@de
Alan Perelson
@es
Alan Perelson
@nl
Alan S. Perelson
@en
Alan S. Perelson
@ga
Перельсон, Алан
@ru
type
label
Alan Perelson
@de
Alan Perelson
@es
Alan Perelson
@nl
Alan S. Perelson
@en
Alan S. Perelson
@ga
Перельсон, Алан
@ru
altLabel
Alan Perelson
@en
prefLabel
Alan Perelson
@de
Alan Perelson
@es
Alan Perelson
@nl
Alan S. Perelson
@en
Alan S. Perelson
@ga
Перельсон, Алан
@ru
P108
P1006
P214
P244
P1006
P106
P1153
7102363214
P184
P19
P21
P213
0000 0001 0931 862X